of other comorbidities. This guideline is limited in commenting on specific groups of gout patients, as more studies of specific patient cohorts are needed in order to make differential recommendations. Additional studies are needed to determine the safety of prolonged and profound treatmentrelated hypouricemia (e.g., SU â‰¤3 mg/dl), an important knowledge gap given that epidemiologic studies have suggested an inverse association of SU concentration with select neurodegenerative disorders Gout